Top 5 Clean Energy Stocks To Buy Right Now

HDFC Securities’s research report on Tech Mahindra

Tech Mahindra delivered poor revenue growth in 1QFY19 while margin performance was better than expected. Revenue stood at USD 1,224mn (-1.6% QoQ, +0.3% CC), vs our estimate of USD 1,228mn. Enterprise (+1.8%, +3.8% CC QoQ) continue to drive growth led by traction in Manufacturing (+2.5% QoQ) and BFSI (+2.9%). Digital (27% of rev, +30% YoY) is growing in-line with industry average and is driving enterprise growth. Telecom (39.6% of rev, -6.3% QoQ) is dragging overall revenue growth; however management sees it as a seasonal blip and expect recovery form 2QFY19E based on deal wins at the end of the quarter. Deal TCV stands at USD 260mn, out of which ~50% is Telecom.

Outlook

Weve factored USD revenue growth of 7.6/10.6% for FY19/20E, implying revenue CQGR of 3.2/2.2% for FY19/20E and factored EBITDA% at 16.7/17.1%. Maintain BUY with a TP of Rs 740 based on 15x FY20E EPS.

For all recommendations report,click here

Top 5 Clean Energy Stocks To Buy Right Now: Xcerra Corporation(XCRA)

Xcerra Corporation (Xcerra or the Company), formerly known as LTX-Credence Corporation, is a global provider of test and handling capital equipment, interface products, test fixtures and related services to the semiconductor and electronics manufacturing industries. We design, manufacture and market products and services that address the broad, divergent requirements of the mobility, industrial, medical, automotive and consumer end markets, offering a comprehensive portfolio of solutions and technologies, and a global network of strategically deployed applications and support resources. We operate in the semiconductor and electronics manufacturing test markets through our atg-Luther & Maelzer, Everett Charles Technologies (ECT), LTX-Credence and Multitest businesses.   Advisors’ Opinion:

  • [By Garrett Baldwin]

    Get an exclusive invitation to meet Tim before everyone else right here.

    Three Stocks to Watch Today: LC, GE, GS
    General Electric Co. (NYSE: GE) has ousted its CEO John Flannery. Shares are up more than 10% as investors celebrated the news. GE has been mired in a slump, particularly its turbine business. The firm’s new CEO is H. Lawrence Culp, Jr., the former CEO of the industrial firm Danaher. Shares of LendingClub Corp.(NYSE: LC) are under pressure after the SEC charged one of the firm’s divisions with mishandling client money. This weekend, the firm reached a settlement with regulators on charges that the firm inflated its revenue and made changes to products to make the firm look healthier than it is. As a result, the firm’s board of directors forced CEO Renaud Laplanche to resign. Goldman Sachs Group Inc.(NYSE: GS) has replaced CEO Lloyd Blankfein, who has stepped down after more than a decade at the helm at one of Wall Street’s most iconic banks. David Solomon – who has previously served as the firm’s president and COO – will now bet the new CEO. His tenure begins at a tough time for Goldman as the bank struggles with lower trading desk revenues. Look for earnings reports today from Cal-Maine Foods Inc. (NASDAQ: CALM) and Xcerra Corp.(NASDAQ: XCRA).

    Follow Money MorningonFacebook, Twitter, and LinkedIn.

  • [By Rich Smith]

    “Robust industry trends” in the semiconductor industry, argues Davidson, give this “leading provider of semiconductor test handlers and … emerging player in the associated contactor and vision inspection markets” an “ample runway for growth.” Cohu’s also in the process of acquiring one of its top competitors, Xcerra Corporation (NASDAQ:XCRA), in a deal slated to close next quarter, which will add scale to Cohu’s business even as it removes a source of price competition.

  • [By Garrett Baldwin]

    The system that could make you $104,000 richer in the next 12 months…

    Darden Restaurants Inc.(NYSE: DRI) leads a fairly busy day of earnings reports. The restaurant management giant easily topped Wall Street profit numbers by reporting earnings per share of $1.34. The average Wall Street estimate was $1.23. The firm also easily topped revenue expectations. DRI shares were up 4.5% this morning. The problems continue to mount for General Electric Co. (NYSE: GE). This morning, JPMorgan Securities slashed its price target for the U.S. conglomerate from $11 to $10 per share. The investment firm cited ongoing challenges to the company’s turbine business. General Electric has been under pressure since the financial crisis, and it was the worst performing stock on the Dow in 2017 before it was ultimately replaced on the index. Shares of Under Armour Inc. (NYSE: UAA) added 3.4% this morning, but the driver wasn’t necessarily positive for the global apparel giant. According to reports, the Baltimore-based sports apparel giant is cutting 3% of its international workforce. That equates to roughly 400 jobs. The company did raise its fiscal 2018 earnings forecast, and issued a revised update of severance costs. Look for earnings reports from Micron Technology Inc. (NASDAQ: MU), Thor Industries Inc.(NYSE: THO), United Natural Foods Inc.(NASDAQ: UNFI), Steelcase Inc. (NYSE: SCS), Scholastic Corp.(NASDAQ: SCHL), and Xcerra Corp.(NASDAQ: XCRA).

    FollowMoney MorningonFacebook,Twitter, andLinkedIn.

Top 5 Clean Energy Stocks To Buy Right Now: TRACON Pharmaceuticals, Inc.(TCON)

TRACON Pharmaceuticals, Inc., incorporated on October 28, 2004, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

TRC105

The Company is developing TRC105 for use in combination with agents that inhibit angiogenesis by targeting the VEGF pathway. VEGF is required for angiogenesis. TRC105 binds to the endoglin receptor at a precise location to inhibit endothelial cell activation and angiogenesis. TRC105 has been studied in over six completed Phase II clinical trials and approximately three completed Phase I clinical trials, and is being dosed in over five Phase II clinical trials. TRC105 is focused on approximately two orphan indications, gestational trophoblastic neoplasia (GTN) and angiosarcoma. The next tier of development includes ongoing Phase II trials in renal cell carcinoma, glioblastoma and hepatocellular carcinoma. The Company has produced formulations of TRC105 for development in ophthalmology, which are developed for the treatment of wet AMD, the cause of blindness in the Western world.

TRC205

The Company’s TRC205 is a humanized, deimmunized anti-endoglin antibody. TRC205 is being developed for the treatment of fibrotic diseases, including nonalcoholic ! steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).

TRC102

The Company is developing TRC102 (methoxyamine hydrochloride) to reverse resistance to specific chemotherapeutics by inhibiting base excision repair (BER). TRC102 interrupts BER by binding within apurinic/apyrimidinic (AP) sites, converting the AP site to a substrate for the enzyme topoisomerase II, which cleaves TRC102-bound deoxy ribonucleic acid (DNA), resulting in an accumulation of DNA strand breaks that trigger cellular apoptosis or programmed cell death. TRC102 is being developed to reverse resistance to Temodar, an alkylating chemotherapeutic, as well as to Alimta and Fludara, two antimetabolite chemotherapeutics. TRC102 began Phase II development through a Phase II clinical trial that combines TRC102 in patients with mesothelioma, as well as a Phase II clinical trial of TRC102 in patients with glioblastoma.

The Company competes with Pfizer, Inc., Acceleron Pharma Inc., Amgen, Inc., MedImmune LLC, OncoMed Pharmaceuticals Inc., Regeneron Pharmaceuticals, Inc., Roche AG, Genfit Corp., Intercept Pharmaceuticals, Inc., Conatus Pharmaceuticals Inc., Galmed Medical Research Ltd., Gilead Sciences, Inc., Immuron Ltd., Shire plc, Mochida Pharmaceutical Co., Ltd., NasVax Ltd., Raptor Pharmaceutical Corp., Takeda Pharmaceutical Company Limited, InterMune, Inc., Boehringer Ingelheim, Biogen Idec., Bristol-Myers Squibb, Celgene Corporation, Fibrogen, Inc., Gilead, Janssen Pharmaceuticals Inc., Novartis AG, Sanofi S.A, Tesaro, Inc. and AbbVie Inc.

Advisors’ Opinion:

  • [By Stephan Byrd]

    TRACON Pharmaceuticals Inc (NASDAQ:TCON) fell 12.3% during trading on Wednesday . The company traded as low as $1.23 and last traded at $1.21. 896,880 shares changed hands during trading, an increase of 112% from the average session volume of 422,831 shares. The stock had previously closed at $1.38.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on TRACON Pharmaceuticals (TCON)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Clean Energy Stocks To Buy Right Now: Equity Commonwealth(EQC)

Equity Commonwealth (EQC), incorporated on October 9, 1986, is an internally managed and self-advised real estate investment trust (REIT). The Company is engaged in the ownership and operation primarily of office buildings in central business district (CBD) and suburban locations throughout the United States. The Company’s two reportable segments include CBD properties and suburban properties. As of December 31, 2014, its portfolio included 156 properties (262 buildings) with a combined 42.9 million square feet. The Company’s portfolio consisted of 40 properties (53 buildings) with a combined 21.9 million square feet located in CBD locations and 116 properties (209 buildings) with a combined 21.0 million square feet located in suburban locations. Eleven of its properties (11 buildings) with a combined 1.8 million square feet are located in Australia.

As on December 31, 2014, the Company had real estate investments in 156 properties (262 buildings) that were leased to approximately 1,800 tenants and 85.8% of the Company’s total square feet were leased. The Company’s principal source of funds for its operations is rents from tenants at its properties. Its tenants include Office Depot, Inc., Expedia, Inc., John Wiley & Sons, Inc, Telstra Corporation Limited, PNC Financial Services Group, United States Government, Royal Dutch Shell plc, J.P. Morgan Chase & Co., Flextronics International Ltd., United Healthcare Services Inc., The Bank of New York Mellon Corp., Carmike Cinemas, Inc., Bankers Life and Casualty Company, Jones Day, Wells Fargo & Co, Level 3 Communications, Inc., Towers Watson & Co, Ballard Spahr LLP and RE/MAX Holdings, Inc.

Advisors’ Opinion:

  • [By Tim Melvin]

    Zell is the Chairman of Equity Commonwealth (NYSE: EQC), an office REIT that he and some activist investors took over back in 2014.

    His management team has spent the last five years selling what they consider to be non-core properties.

  • [By Shane Hupp]

    Ffcm LLC increased its position in Equity Commonwealth (NYSE:EQC) by 97.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 39,928 shares of the real estate investment trust’s stock after acquiring an additional 19,711 shares during the quarter. Ffcm LLC’s holdings in Equity Commonwealth were worth $1,198,000 at the end of the most recent quarter.

  • [By Matthew DiLallo]

    Equity Commonwealth (NYSE:EQC) continued the steady pare-down of its property portfolio during the fourth quarter, ending the year with only 10 remaining real estate assets. However, for the first time in years, the company’s funds from operations increased as it was able to more than offset the lost income with gains elsewhere. But it’s not yet clear whether the company’s earnings growth will continue, since it has several more property sales in the works, which could weigh on its results until it starts making acquisitions.

Top 5 Clean Energy Stocks To Buy Right Now: Fisher(j)

James Fisher and Sons plc, together with its subsidiaries, provides marine services and specialist engineering services in the United Kingdom, Ireland, Norway, and internationally. The company operates through four segments: Specialist Technical Services, Offshore Oil Services, Defence, and Marine Oil. The Specialist Technical Services engages in the hire and sale of large scale pneumatic fenders; provision of ship to ship transfer services; and design and supply of systems for monitoring strains and stress in structures and equipment. This segment also offers non-destructive testing services; and design, engineering, and manufacturing services for the nuclear decommissioning industries. The Offshore Oil Services segment manufactures and rents equipment for the offshore oil and gas industry; and designs and manufactures specialist down hole tools and equipment for extracting oil. This segment also offers related specialist labor, such as cranes, winches and pumps to the of fshore sector, wind farms, and for subsea operations. The Defence segment designs, constructs, and operates submarine rescue vehicles and remotely operated vehicles; and operates surface ships. It offers marine services to the Ministry of Defence (MoD) and other navies, including the United Kingdom; maintenance, asset management, and consultancy services; military strategic sealift capability through its operation of six roll on ? roll off vessels for the MoD; and submarine rescue services to the government of Singapore. The Marine Oil segment is involved in the sea transportation of clean petroleum products in north west Europe; and wharf operations. The company was founded in 1847 and is headquartered in Barrow-in-Furness, the United Kingdom.

Advisors’ Opinion:

  • [By Logan Wallace]

    Joincoin (CURRENCY:J) traded 22.3% higher against the dollar during the 1 day period ending at 9:00 AM E.T. on October 2nd. Joincoin has a total market capitalization of $95,205.00 and $22.00 worth of Joincoin was traded on exchanges in the last 24 hours. During the last seven days, Joincoin has traded 6.1% lower against the dollar. One Joincoin coin can now be bought for approximately $0.0299 or 0.00000456 BTC on major cryptocurrency exchanges.

  • [By Logan Wallace]

    Joincoin (CURRENCY:J) traded 12.5% higher against the dollar during the 24-hour period ending at 10:00 AM ET on September 30th. Joincoin has a market cap of $98,508.00 and $17.00 worth of Joincoin was traded on exchanges in the last day. One Joincoin coin can now be bought for $0.0309 or 0.00000467 BTC on popular exchanges. During the last seven days, Joincoin has traded 8.2% lower against the dollar.

  • [By Shane Hupp]

    Joincoin (J) is a proof-of-work (PoW) coin that uses the Multiple hashing algorithm. Its launch date was August 13th, 2014. Joincoin’s total supply is 3,173,702 coins. Joincoin’s official website is bitcointalk.org/index.php?topic=737405.0. Joincoin’s official Twitter account is @Joincoin_Team.

  • [By Joseph Griffin]

    Joincoin (CURRENCY:J) traded 1.7% lower against the U.S. dollar during the 24 hour period ending at 0:00 AM ET on May 8th. Joincoin has a total market cap of $145,714.00 and $7.00 worth of Joincoin was traded on exchanges in the last 24 hours. During the last week, Joincoin has traded up 28.6% against the U.S. dollar. One Joincoin coin can currently be bought for about $0.0471 or 0.00000521 BTC on cryptocurrency exchanges.

Top 5 Clean Energy Stocks To Buy Right Now: Marathon Oil Corporation(MRO)

Marathon Oil Corporation, through its subsidiaries, operates as an international energy company with operations in the United States, Canada, Africa, the Middle East, and Europe. It operates through three segments: Exploration and Production, Oil Sands Mining, and Integrated Gas. The Exploration and Production segment explores for, produces, and markets liquid hydrocarbons and natural gas. The Oil Sands Mining segment mines, extracts, and transports bitumen from oil sands deposits in Alberta, Canada; and upgrades the bitumen to produce and market synthetic crude oil and vacuum gas oil. The Integrated Gas segment markets and transports products manufactured from natural gas, such as liquified natural gas and methanol. The company was formerly known as USX Corporation and changed its name to Marathon Oil Corporation in July 2001. Marathon Oil Corporation was founded in 1887 and is based in Houston, Texas.

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Marathon Oil (NYSE:MRO) based its 2019 plans on oil averaging $50 a barrel. At that price point, the company can fund its $2.6 billion capital spending plan — enough money to grow its U.S. oil production by 12% this year — and its dividend with plenty of room to spare. Marathon has so much breathing room that it can fund its 2019 budget as well as its dividend at $45 oil, which means it’s on track to produce a gusher of free cash now that oil is in the mid-$50s. Marathon currently expects to return the bulk of that money to shareholders through additional share repurchases, which sets up investors to potentially earn some high-octane total returns this year if oil keeps going higher.

  • [By Matthew DiLallo]

    Marathon Oil (NYSE:MRO) delivered exceptional operational and financial results in 2018. Not only did its U.S. oil production outperformthe midpoint of its initial guidance range by 22.5%, but it also generated a boatload of free cash flow. That strong performance is one of many reasons Marathon CEO Lee Tillman believes his company checks all the boxes for investors. He laid out the case for the company on itsfourth-quarter conference call, detailing four reasons Marathon is an ideal oil stock. Here’s what he said.

Leave a Reply

Your email address will not be published. Required fields are marked *